AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
暂无分享,去创建一个
Alan McClelland | Arthur Thompson | Roland W Herzog | Bertil Glader | M. Kay | M. Ozelo | R. Herzog | K. High | C. Manno | M. Ragni | P. Larson | L. Couto | A. Mcclelland | B. Glader | A. Chew | S. J. Tai | V. Arruda | F. Johnson | C. Scallan | E. Skarsgard | A. Flake | A. Thompson | D. Leonard | Ciaran Scallan | Erik Skarsgard | Mark A Kay | Catherine S Manno | Katherine A High | Alan W Flake | Linda B Couto | Margaret V Ragni | Valder R Arruda | Amy J Chew | Sylvia Hutchison | Peter J Larson | Shing Jen Tai | Margareth Ozelo | Debra G B Leonard | Frederick A Johnson | S. Hutchison
[1] K. High,et al. Immune Responses in Gene Transfer for Genetic Disorders , 2003 .
[2] D. Girelli,et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis , 2003, Nature Genetics.
[3] M. Loda,et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. , 2002, Blood.
[4] W. Sly,et al. Decreased liver hepcidin expression in the Hfe knockout mouse. , 2002, Blood cells, molecules & diseases.
[5] R. Herzog,et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.
[6] W. Forssmann,et al. Chemical synthesis of β-defensins and LEAP-1/hepcidin , 2002 .
[7] R. Herzog,et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.
[8] J. Burns,et al. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. , 2002, European journal of biochemistry.
[9] N. Andrews. Metal transporters and disease. , 2002, Current opinion in chemical biology.
[10] A. Giles,et al. The Utility of activated Partial Thromboplastin Time (aPTT) Clot Waveform Analysis in the Investigation of Hemophilia A Patients with very Low Levels of Factor VIII Activity (FVIII:C) , 2002, Thrombosis and Haemostasis.
[11] P. Grammatico,et al. Absence of hepcidin gene mutations in 10 Italian patients with primary iron overload. , 2002, Haematologica.
[12] N. Boyce. Trial halted after gene shows up in semen , 2001, Nature.
[13] G. Blancho,et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] J. Biegel,et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[15] P. Aisen,et al. Chemistry and biology of eukaryotic iron metabolism. , 2001, The international journal of biochemistry & cell biology.
[16] R. Herzog,et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] C. Beaumont,et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] Christina H. Park,et al. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.
[19] J. Huh,et al. Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. , 2001, Journal of molecular and cellular cardiology.
[20] R. Herzog,et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. , 2001, Blood.
[21] C. Enns,et al. Iron homeostasis: new tales from the crypt. , 2000, Blood.
[22] R. Samulski,et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] G. Cairo,et al. Iron regulatory proteins in pathobiology. , 2000, The Biochemical journal.
[24] Peter Schulz-Knappe,et al. LEAP‐1, a novel highly disulfide‐bonded human peptide, exhibits antimicrobial activity , 2000, FEBS letters.
[25] L. Cowan,et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. , 2000, Blood.
[26] D. Bohl,et al. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. , 2000, Blood.
[27] J. Mendell,et al. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. , 2000, Human gene therapy.
[28] H. Ertl,et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[29] R. Samulski,et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. , 2000, Human gene therapy.
[30] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[31] I. Verma,et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] Shapiro,et al. A Multicenter Study of Recombinant Factor VI11 (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A , 2000 .
[33] K. Propert,et al. Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.
[34] S. Bauer,et al. FDA comments on phase I clinical trials without vector biodistribution data , 1999, Nature Genetics.
[35] James M. Wilson,et al. Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.
[36] S. Bidlingmaier,et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Molkentin,et al. Calcineurin and human heart failure , 1999, Nature Medicine.
[38] V. Braun,et al. Bacterial solutions to the iron-supply problem. , 1999, Trends in biochemical sciences.
[39] N. Andrews. Disorders of iron metabolism. , 1999, The New England journal of medicine.
[40] Gene therapy and the germline , 1999, Nature Medicine.
[41] Katherine A. High,et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.
[42] M. Kay,et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.
[43] L. Villarreal,et al. Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.
[44] K. Kurachi,et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. , 1998, Blood.
[45] S. Kung,et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.
[46] R. Ljung. Can haemophilic arthropathy be prevented? , 1998, British journal of haematology.
[47] T. Flotte,et al. A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, California , 1998 .
[48] J. Rouse,et al. Biochemical characterization of recombinant factor IX. , 1998, Seminars in hematology.
[49] A. Giles,et al. The Canine Factor VIII cDNA and 5’ Flanking Sequence , 1998, Thrombosis and Haemostasis.
[50] R. Samulski,et al. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.
[51] T. Flotte,et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. , 1998, Human gene therapy.
[52] K. High,et al. Gene therapy for the hemophilias. , 1999, Advances in veterinary medicine.
[53] N. Maeda,et al. A coagulation factor IX-deficient mouse model for human hemophilia B. , 1997, Blood.
[54] M. Zoppè,et al. A factor IX-deficient mouse model for hemophilia B gene therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[55] A. Gown,et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.
[56] James M. Wilson,et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] H. Pettersson,et al. Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.
[58] James M. Wilson,et al. Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.
[59] D. Russell,et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[60] B. Byrne,et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[61] R. Samulski,et al. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.
[62] P. Simmonds,et al. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus , 1996, British journal of haematology.
[63] K. Whitney,et al. A deletion mutation causes hemophilia B in Lhasa Apso dogs. , 1996, Blood.
[64] P. Simmonds,et al. Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non‐invasive methods , 1996, British journal of haematology.
[65] S. Antonarakis,et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.
[66] K. Kurachi,et al. Role of Intron I in Expression of the Human Factor IX Gene (*) , 1995, The Journal of Biological Chemistry.
[67] E. Gordon,et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.
[68] R. Ellison. The effects of lactoferrin on gram-negative bacteria. , 1994, Advances in experimental medicine and biology.
[69] Donald W. Pfaff,et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.
[70] S. Arkin,et al. Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors , 1993 .
[71] S. Arkin,et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.
[72] D. Bentley,et al. Genetics and molecular biology of haemophilias A and B. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[73] J Cairns,et al. Cold spring harbor. , 1991, Science.
[74] J. Ware,et al. Molecular cloning of a cDNA encoding canine factor IX. , 1989, Blood.
[75] G. Bray,et al. Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy. , 1987, American journal of diseases of children.
[76] L. Bianchi,et al. A study of liver biopsies and liver disease among hemophiliacs. , 1985, Blood.
[77] W. Andes,et al. Head trauma in hemophilia. A prospective study. , 1984, Archives of internal medicine.
[78] M. Hilgartner,et al. Central nervous system bleeding in hemophiliacs. , 1978, Blood.
[79] M. Johnson,et al. Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. , 1973, Journal of the neurological sciences.
[80] G. Cinotti,et al. [Neurologic complications of hemophilia]. , 1957, Rassegna di fisiopatologia clinica e terapeutica.